Eribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT01908101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Trial of Metronomic Eribulin (Halaven) in Pretreated Metastatic Breast Cancer (MBC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well eribulin mesylate works in treating patients with previously treated breast cancer that has spread to other places in the body. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Study identification
- NCT ID
- NCT01908101
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2014
- Primary completion
- May 3, 2019
- Completion
- May 3, 2019
- Last update posted
- Jul 22, 2020
2014 – 2019
United States locations
- U.S. sites
- 12
- U.S. states
- 5
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Katmai Oncology Group | Anchorage | Alaska | 99508 | — |
| Providence Alaska Medical Center | Anchorage | Alaska | 99508 | — |
| The University of Arizona Medical Center-University Campus | Tucson | Arizona | 85724 | — |
| Bozeman Deaconess Hospital | Bozeman | Montana | 59715 | — |
| Bend Memorial Clinic | Bend | Oregon | 97701 | — |
| Kadlec Clinic Hematology and Oncology | Kennewick | Washington | 99336 | — |
| Skagit Valley Hospital | Mount Vernon | Washington | 98274 | — |
| Olympic Medical Center | Port Angeles | Washington | 98362 | — |
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
| Group Health Cooperative-Seattle | Seattle | Washington | 98112 | — |
| MultiCare Tacoma General Hospital | Tacoma | Washington | 98405 | — |
| Wenatchee Valley Hospital and Clinics | Wenatchee | Washington | 98801 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01908101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2020 · Synced Sep 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01908101 live on ClinicalTrials.gov.